Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Atara Biotherapeutics, Inc. is not a good value stock. Atara Biotherapeutics, Inc. is not very popular among insiders. Atara Biotherapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel t...
ATRA Fundamental Data by TradingView

News

Atara Biotherapeutics (NASDAQ:ATRA) Shares Cross Below Fifty Day Moving Average of $8.69
Atara Biotherapeutics (NASDAQ:ATRA) Shares Cross Below Fifty Day Moving Average of $8.69

Zolmax Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report)'s stock price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $8.69 and...\n more…

Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $185.50
Brokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $185.50

Zolmax Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) has earned a consensus rating of "Hold" from the five analysts that are currently covering the company, MarketBeat reports. One equities...\n more…

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...\n more…

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St Those holding Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares would be relieved that the share price has rebounded...\n more…

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...\n more…

Atara Biotherapeutics Announces Board Appointment and Capital Raise
Atara Biotherapeutics Announces Board Appointment and Capital Raise

TipRanks Financial Blog The latest announcement is out from Atara Biotherapeutics (ATRA). Atara Biotherapeutics, Inc. has announced the appointment of Mr. Gregory A. Ciongoli to its Board ...\n more…